Vnitr Lek 2022, 68(7):475-478 | DOI: 10.36290/vnl.2022.104

Můžeme novou léčbou ovlivnit dosavadní terapií neřešený zánět a fibrózu u pacientů s DM2 a CKD?

Milan Kvapil
Interní klinika 2. LF UK a FN Motol

Published: October 31, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kvapil M. Můžeme novou léčbou ovlivnit dosavadní terapií neřešený zánět a fibrózu u pacientů s DM2 a CKD? Vnitr Lek. 2022;68(7):475-478. doi: 10.36290/vnl.2022.104.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ryšavá R. Viklický O et al. Doporučené postupy v nefrologii. Maxdorf: Praha; 2022.
    2. Fujisawa G, Okada K, Muto S et al. Spironolactone prevents early renal injury in streptozotocin‑induced diabetic rats. Kidney Int. 2004;66(4):1493-502. Go to original source... Go to PubMed...
    3. Han S‑Y, Kim CH, Kim H‑S et al. Spironolactone prevents diabetic nephropathy through an anti‑inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol. 2006;17(5):1362-72. Go to original source... Go to PubMed...
    4. Agarwal R, Kolkhof P, Bakris G, Bauersachs J, Haller H, Wada T, Zannad F. Steroidal and non‑steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021;42(2):152-161. Go to original source... Go to PubMed...
    5. Bakris GL, Agarwal R, Chan JC et al. Mineralocorticoid Receptor Antagonist Tolerability Study-Diabetic Nephropathy (ARTS‑DN) Study Group. Eff ect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA. 2015;314(9):884-94. Go to original source... Go to PubMed...
    6. Bakris GL, Agarwal R, Anker SD et al. FIDELIO‑DKD Investigators. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020; 383(23):2219-2229. Go to original source... Go to PubMed...
    7. Rossing P, Agarwal R, Anker SD et al. FIDELIO‑DKD Investigators. Efficacy and safety of finerenone in patients with chronic kidney dinase and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO‑DKD trial. Diabetes Obes Metab. 2022;24(1):125-134. Go to original source... Go to PubMed...
    8. Rossing P, Filippatos G, Agarwal R et al. FIDELIO‑DKD Investigators. Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium‑Glucose Cotransporter-2 Inhibitor Therapy. Kidney Int Rep. 2021;7(1):36-45. Go to original source... Go to PubMed...
    9. Filippatos G, Anker SD, Agarwal R, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Schloemer P, Tornus I, Joseph A, Bakris GL; FIDELIO‑DKD Investigators. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. Circulation. 2021 Feb 9;143(6):540-552. Go to original source... Go to PubMed...
    10. Souhrn údajů o přípravku Kerendia®. Available from: https://www.bayer.com/sites/default/files/Kerendia_SPC.pdf. Nahlíženo 07. 10. 2022

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.